Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE‐A-Reference-Cited by-同舟云学术

Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE‐A

Published:2022-09-16 Issue:11 Volume:97 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Pratz Keith W.¹^ORCID,DiNardo Courtney D.²^ORCID,Selleslag Dominik³,Li Junmin⁴,Yamamoto Kazuhito⁵,Konopleva Marina²^ORCID,Stevens Don⁶,Kantarjian Hagop²^ORCID,Traina Fabiola⁷,Venditti Adriano⁸^ORCID,Mayer Jiri⁹,Montez Melissa¹⁰,Jin Huan¹⁰,Duan Yinghui¹¹,Brackman Deanna¹¹,Zha Jiuhong¹¹,Potluri Jalaja¹¹,Werner Michael¹¹,Jonas Brian A.¹²^ORCID

Affiliation:

1. Department of Medicine Hematology‐Oncology Section, Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA

2. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA

3. Algemeen Ziekenhuis Sint Jan Brugge‐Oostende Belgium

4. Ruijin Hospital Shanghai China

5. Aichi Cancer Center Chikusa‐ku Nagoya Japan

6. Norton Cancer Institute Louisville Kentucky USA

7. Department of Medical Imaging, Haematology, and Oncology University of São Paulo at Ribeirão Preto Medical School Sao Paulo Brazil

8. Hematology, Department of Biomedicine and Prevention University Tor Vergata Rome Italy

9. University Hospital Brno and Masaryk University Brno Czech Republic

10. Genentech, Inc South San Francisco California USA

11. AbbVie, Inc North Chicago Illinois USA

12. Department of Internal Medicine, Division of Hematology and Oncology University of California Davis School of Medicine Sacramento California USA

Funder

AbbVie

Genentech

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26692

Reference1 articles.

1. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML;Leukemia Research;2024-08

2. Ven the dose matters: Venetoclax dosing in the frontline treatment of AML;Blood Reviews;2024-08

3. Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?;American Journal of Hematology;2024-07-17

4. Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia;Blood Neoplasia;2024-06

5. Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia;Cancer Chemotherapy and Pharmacology;2024-05-23